Smart Hydrogen Bandages Speed Healing of Diabetic Foot Wounds
- Authors
- Xiaona Wang, Lei Pan, Haijun Shen
- Journal
- Diabetology & Metabolic Syndrome
- Year
- 2026
- DOI
- 10.1186/s13098-026-02181-5
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Diabetic Foot Ulcers
- Body System
- Integumentary
TL;DR
Scientists tested special bandages made from smart materials that release hydrogen to help heal diabetic foot wounds, and the early animal studies showed these bandages work really well by reducing inflammation and helping the wound close faster. This matters because diabetic foot ulcers are super hard to treat, so finding a new material that could heal them better could help millions of people with diabetes.
Key Finding
In preclinical animal models, hydrogen-delivering biomaterial carriers significantly improved diabetic wound healing by enhancing closure rates, stimulating new blood vessel formation, and reducing inflammatory markers like TNF-α and IL-6.
Summary
This review examined 11 animal studies testing special materials that deliver hydrogen gas to help heal diabetic foot ulcers (wounds that don't heal well in people with diabetes). The materials—such as hydrogen-releasing gels and special bandages—were designed to slowly release hydrogen directly into the wound. The studies found that hydrogen delivery improved wound closure, promoted new blood vessel growth, and reduced inflammation and oxidative stress (cellular damage from harmful molecules).
Practical Takeaway
While these results are promising, this review only examined animal studies—not human trials. The findings suggest hydrogen delivery systems may have potential for treating diabetic foot ulcers, but much more research in humans is needed before any clinical use. The researchers emphasize that optimization and safety testing in human patients would be necessary steps before this approach could be considered a viable treatment.
Abstract
Objective: This study aimed to systematically evaluate the preclinical evidence on the therapeutic efficacy and underlying mechanisms of hydrogen-delivering biomaterial carriers in the treatment of diabetic foot ulcer (DFU). Method: We conducted a comprehensive search across eight databases (PubMed, Web of Science, Embase, Cochrane Library, CBM, CNKI, Wanfang, and VIP) to identify randomized animal studies investigating biomaterial-based hydrogen delivery for DFUs from database inception through November 2025. After screening, eleven studies met inclusion criteria and were included in the final meta-analysis. Data synthesis and statistical analyses were performed using RevMan 5.4; risk of bias was assessed using the SYRCLE's tool for animal studies. Results: The delivery of hydrogen via biomaterial carriers effectively promotes diabetic wound repair by enhancing wound closure rates, stimulating angiogenesis, and improving collagen deposition. Smart delivery systems, such as hydrogen-generating hydrogels, responsive microneedle patches, and photocatalytic dressings, enabled spatiotemporally controlled, sustained H₂ release. This modulation effectively attenuated oxidative stress and suppressed pro-inflammatory cytokine expression (e.g., TNF-α, IL-6). Collectively, biomaterial-mediated hydrogen delivery confers dual therapeutic actions: direct promotion of tissue regeneration and dynamic reprogramming of the impaired wound microenvironment, supporting its potential as a targeted, mechanism-informed intervention for DFUs. Conclusion: Biomaterial-based hydrogen delivery systems demonstrate multifaceted therapeutic benefits in preclinical DFU models, primarily through anti-inflammatory, pro-angiogenic, and collagen-enhancing mechanisms. The emergence of smart delivery systems enables localized, tunable, and prolonged hydrogen release, which improves bioavailability and therapeutic precision. Future research should prioritize optimization of release kinetics, pharmacokinetic-pharmacodynamic modeling in diabetic wound beds, and exploration of synergistic combinations (e.g., with growth factors or antimicrobial agents) to advance toward clinically translatable, precision wound therapeutics.